In mice, cannabinoid receptor drugs prevented—but did not reverse—sensitization

Cannabinoid actions in a nonsurgical mouse model of sensitized dural nociceptors.

Pain • • Highly Relevant
🤖

AI Summary

This animal study asked whether cannabinoid receptor drugs could prevent or reverse acid-triggered sensitivity in the tissues around the brain’s outer covering. In female mice, an injection of acidic saline caused temporary sensitivity around the eye, and a later, milder-acid challenge brought back sensitivity after the initial response had recovered. The study tested these effects in mice and in isolated dural trigeminal ganglion neurons; it was not a human clinical trial.

When given alongside the initial acidic injection, PrNMI, which activates CB1 and CB2 receptors, prevented both the initial and later sensitivity. The CB1-selective drug ACEA also prevented it, while the CB2-selective drug RNB61 did not. PrNMI did not prevent sensitivity when given only at the later challenge, after sensitization had occurred. In isolated neurons, PrNMI reduced acid-triggered activity in cells from control mice, but not in cells from acid-treated mice. These findings suggest a preventive effect requiring combined receptor activity, not a demonstrated way to reverse established sensitivity. This abstract-based summary cannot establish whether the approach is safe or effective in people; the study used a specific mouse model and reports no human outcomes.

💡 Key Findings

1
In female mice, PrNMI given with the initial acidic injection prevented both initial and later periorbital allodynia.
Good
70%
2
The CB1-selective agonist ACEA also prevented allodynia, while the CB2-selective agonist RNB61 alone did not.
Good
70%
3
PrNMI given after sensitization had developed did not prevent the later allodynia, indicating that the preventive result did not demonstrate reversal.
Good
70%
4
In isolated dural sensory neurons, PrNMI suppressed acid-induced depolarization in cells from control, but not acid-treated, mice; RNB61 had no effect.
Good
60%

📄 Original Abstract

Cannabinoid 1 and 2 receptor (CB1R and CB2R) agonists alleviate inflammatory and neuropathic pain symptoms. However, central nervous system (CNS) side effects mediated by CB1Rs limit their widespread use. We developed peripherally restricted cannabinoids (PRCBs), which exhibit analgesic efficacy with minimal CNS side effects. Here, we examined PRCB actions in a mouse model of dural acid-induced hypersensitivity. Supradural injections of pH-6.0 (but not pH-7.4) saline (4.5 µL) in five-week-old female C57BL/6J mice induced periorbital allodynia (assessed with von Frey filaments) with recovery by 48 hours. By 72 hours, allodynia was elicited with a supradural pH-7.0 saline injection in pH-6.0 (but not pH-7.4) mice. The CB1R/CB2R agonist PRCB, 4-{2-[(1E)-1-[(4-propylnaphthalen-1-yl) methylidene]-1H-inden-3-yl]ethyl}morpholine (PrNMI) (5 µM) or the selective CB1R agonist arachidonyl-2'-chloroethylamide (ACEA, 5 µM), coapplied with pH-6.0 saline, prevented both the initial and latent allodynia, but coadministering pH 6.0 with the CB2R-selective agonist RNB61 (5 µM) did not. Coadministering pH-6.0/PrNMI with CB1R- or CB2R-selective inverse agonists abolished the preventative effects of PrNMI. Supradural pH-6.0 saline-evoked allodynia followed 72 hours later by coadministration of pH 7.0/PrNMI did not prevent latent allodynia. Patch recordings obtained from dural trigeminal ganglion neurons (dTGNs) acutely isolated from FluoroGold/pH-6.0 (but not pH-7.4)-injected mice had larger acid-induced depolarizations. All dTGNs had electrophysiological properties of Aδ- or C-type nociceptors. PrNMI (1 µM) suppressed acid-induced depolarizations in dTGNs from pH-7.4 (but not pH-6.0)-treated mice, whereas RNB61 (0.5 µM) had no effect. These findings indicate that PrNMI prevents acid-induced sensitization by coactivating neuronal CB1Rs and non-neuronal CB2Rs. Cannabinoid 2 receptor activation alone is insufficient, and once sensitized, combined CB1R/CB2R activation loses efficacy.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.